Obesity has become a chronic disease affecting whole-body health, yet traditional lifestyle interventions and drug therapy face challenges such as difficulty sustaining long-term results and limited efficacy in some patients. Against this background, bariatric and metabolic surgery is attracting increasing attention for its established efficacy and durable benefits.
At the 2026 Obesity Conference (COC 2026), Prof. Zhongtao Zhang delivered a systematic talk on “The Development, Mechanisms and Clinical Value of Bariatric and Metabolic Surgery,” providing an in-depth analysis of how metabolic surgery has moved beyond weight reduction to regulate glucose and lipid metabolism, reduce cardiovascular risk, and even influence the natural history of disease.
From “Weight Loss” to “Disease Treatment”: Metabolic Surgery Redefines the Goal of Obesity Management
For a long time, obesity treatment has focused on weight change. As research has deepened, however, clinical understanding has shifted: obesity is not a matter of body shape alone, but a complex disease involving metabolic dysregulation, inflammatory states, and multi-organ damage.
Prof. Zhang reviewed more than seventy years of evolution in bariatric and metabolic surgery. The 1950s–70s were an exploration period: early jejunoileal bypass surgery was abandoned because of severe complications, while Mason’s 1966 gastric bypass laid the foundation for modern bariatric surgery. The 1980s–90s were a period of evolution, with continuous refinement of procedures, culminating in the successful laparoscopic gastric bypass in 1994 and marking the start of the minimally invasive era. The 21st century to the present is an elevation period: clinical evidence shows that surgery produces not only weight loss but also significant improvement in type 2 diabetes, hypertension and other metabolic diseases, pushing the discipline to evolve from “bariatric surgery” into “bariatric and metabolic surgery,” with the treatment goal shifting from weight loss alone to comprehensive metabolic disease management. Prof. Zhang stressed that early procedures focused mainly on weight loss, while current priorities include improvement in obesity-related metabolic abnormalities such as type 2 diabetes, fatty liver disease and cardiovascular risk.
Mechanisms of Metabolic Improvement: Multi-Pathway Synergy Underpins the Therapeutic Basis
The value of bariatric and metabolic surgery goes well beyond reduced gastric volume or decreased food intake; it involves a complex network of physiological regulation. Prof. Zhang noted that the mechanisms of benefit are highly complex and are currently understood to involve multi-level physiological regulation, with the principal postoperative improvements seen in the following areas:
- l changes in gastrointestinal hormone secretion;
- l improvement in insulin sensitivity;
- l correction of disordered glucose and lipid metabolism;
- l modulation of inflammatory responses and gut-related metabolic pathways.
Particularly noteworthy is that Prof. Zhang’s team, using small-animal models of bariatric and metabolic surgery, has explored the “phenotype–metabolic network” regulatory mechanisms through which surgery treats fatty liver disease. The team’s research suggests that some of the metabolic benefits of metabolic surgery arise through non-weight-dependent pathways — that is, some metabolic improvements occur directly, independently of weight loss. These findings are pushing clinical practice from “managing weight indicators” toward “managing metabolic health.”
Long-Term Benefits Are Increasingly Clear: Metabolic Surgery Reduces Disease Risk and Improves Survival Outcomes
To evaluate the clinical value of a treatment, one must look beyond short-term efficacy and consider whether it can deliver long-term disease improvement and survival benefit. Prof. Zhang presented a systematic picture of the clinical gains of metabolic surgery across multiple dimensions.
In cardiovascular benefits, metabolic surgery not only produces sustained, stable weight loss but is also closely linked to a reduction in cardiovascular event risk. Prof. Zhang noted that abnormalities in glucose, blood pressure and lipids are the main drivers of obesity-related disease burden in China; by intervening on these core links, metabolic surgery offers an effective pathway for reducing long-term cardiovascular events.
In fatty liver disease, Prof. Zhang placed particular emphasis on “remission of steatohepatitis and reversal of liver fibrosis.” Obesity-related fatty liver disease is highly prevalent in bariatric-surgery populations, and traditional weight management has only limited efficacy against it. Metabolic surgery, by contrast, shows distinctive therapeutic potential — not only reducing hepatic fat deposition but also potentially achieving remission of steatohepatitis and reversal of liver fibrosis, marking an important extension of metabolic surgery from “weight-loss tool” to “organ-protective therapy.”
In addition, the disease-burden profile of obesity in China cannot be ignored. Studies project that by 2050, the proportion of overweight and obese Chinese adults will approach 65%, with the obesity burden increasingly concentrated at both the younger and older ends of the age spectrum. Metabolic risk factors — hypertension, hyperglycemia and dyslipidemia — form the main share of obesity-related disease burden in China. This stark context further highlights the important place of metabolic surgery in multidisciplinary comprehensive management.
Conclusion
Although metabolic surgery already has substantial evidence-based support, clinical practice still faces challenges in patient selection, choice of procedure, long-term follow-up and comprehensive management. For clinicians, repositioning metabolic surgery means more than mastering a procedure; it means establishing a disease-management philosophy centered on the patient’s overall health benefit. As Prof. Zhang emphasized at the end of his talk, the future of obesity treatment requires further advancing the multidisciplinary collaboration model, integrating surgery, endocrinology, nutrition and exercise medicine to deliver full life-cycle management for patients.